EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study

Robert Zeiser iD, Domenico Russo iD, Ron Ram iD, Shahrukh K Hashmi iD, Ronjon Chakraverty iD, Jan Moritz Middeke iD, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad iD, Karin Burock und 5 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-02477 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Robert Zeiser und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Graft vs Host Disease, Pyrazoles, Adrenal Cortex Hormones. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In REACH3 (ClinicalTrials.gov identifier: NCT03112603 ), ruxolitinib was investigated versus best available therapy (BAT) for 3 years in patients with steroid-refractory/dependent chronic graft-versus-host-disease (SR/D-cGVHD). Patients received ruxolitinib (10 mg twice daily) or BAT for 24 weeks; thereafter (weeks 24-156), patients continued randomized treatment, entered long-term survival follow-up, or crossed over from BAT to ruxolitinib. In 329 randomly assigned patients (ruxolitinib: 165; BAT: 164), the median failure-free survival (FFS) was 38.4 months for ruxolitinib versus 5.7 months for BAT (hazard ratio, 0.36 [95% CI, 0.27 to 0.49]). Median duration of response (DOR) was not reached for ruxolitinib versus 6.4 months for BAT. Ruxolitinib-treated patients had a higher probability of FFS (ruxolitinib: 56.5%; BAT: 18.2%) and maintaining a response (ruxolitinib: 59.6%; BAT: 26.7%) at 36 months. Median overall survival was not reached. Nonrelapse mortality and malignancy relapse/recurrence events were low. In 70 patients who crossed over to ruxolitinib, the overall response rate (50.0%) at week 24 and best overall response (81.4%) during the crossover period were consistent with the primary analysis of randomly assigned patients. No new safety signals were observed. Ruxolitinib provided longer FFS and DOR than BAT, demonstrating sustained efficacy and manageable safety over 3 years of follow-up in patients with SR/D-cGVHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseasePyrazolesAdrenal Cortex HormonesHumansNitrilesPyrimidinesFemaleMaleMiddle AgedAdultChronic DiseaseAgedYoung AdultCross-Over Studies

Substanzen

ruxolitinibNitrilesPyrimidinesPyrazolesAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany.
  • Unit of Blood Diseases and Bone Marrow Transplantation, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.
  • BMT Unit, Tel Aviv (Sourasky) Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Department of Medicine, Sheikh Shakhbout Medical City, Mayo Clinic, Abu Dhabi, UAE and Department of Medicine, Mayo Clinic, Rochester, MN.
  • Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden, and National Center for Tumor Diseases (NCT) Dresden, Dresden, Germany.

ORCID-Profile: Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Nada Hamad, Stephanie J Lee, Takanori Teshima, Franco Locatelli

Zitieren

APA

Zeiser, R., Russo, D., Ram, R., Hashmi, S. K., Chakraverty, R., Middeke, J. M., Musso, M., Giebel, S., Uzay, A., Langmuir, P., Hamad, N., Burock, K., Gowda, M., Stefanelli, T., Lee, S. J., Teshima, T., & Locatelli, F. (2025). Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02477

Vancouver

Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-02477

BibTeX
@article{Zeiser2025,
  author = {Zeiser, Robert and Russo, Domenico and Ram, Ron and Hashmi, Shahrukh K and Chakraverty, Ronjon and Middeke, Jan Moritz and Musso, Maurizio and Giebel, Sebastian and Uzay, Ant and Langmuir, Peter and Hamad, Nada and Burock, Karin and Gowda, Maanasa and Stefanelli, Tommaso and Lee, Stephanie J and Teshima, Takanori and Locatelli, Franco},
  title = {Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-02477}
}
Kostenlos starten →